Cardiology

Study finds higher Ischemic events and mortality in transcatheter valve replacement patients taking non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists.

Low-risk atrial fibrillation patients who take oral anticoagulants have a lower risk of dementia than those who do not, a study says.

The use of direct‐acting oral anticoagulants has increased among nursing home residents with atrial fibrillation.

Overestimating the bleeding risk of anticoagulants may lead to poor compliance.

Fragmin, a low-molecular-weight heparin dalteparin sodium injection, was approved for symptomatic venous thromboembolism.

Two different versions of tafamadis get the FDA’s nod to treat a rare heart disease. 

Bleeding in patients with nonvalvular atrial fibrillation and coronary syndrome was reduced by apixaban versus vitamin K antagonists.

Many kidney disease patients with atrial fibrillation are not treated with anticoagulation, increasing their risk of stroke.

Study finds different anticoagulation treatment levels for patients with cognitive problems.

A meta-analysis of 95 studies indicates lower risk of stroke and intracranial hemorrhage.

Higher-dose tofacitinib linked to greater risk of pulmonary embolism in RA patients.

What you need to know about the von Willebrand factor (vWF)-directed antibody fragment.

DOACs are as good as warfarin in preventing atrial fibrillation complications.

Three cardiology groups now recommend using NOACs over warfarin in atrial fibrillation.

Black patients with atrial fibrillation are less likely to be treated with oral anticoagulants or DOACs.

The risk of gastrointestinal bleeding appears to be highest with rivaroxaban and lowest with apixaban, but is reduced by cotherapy with proton pump inhibitors.

Patients with atrial fibrillation who have had cancer are less likely to see a cardiologist and less likely to fill anticoagulant prescriptions.

A new study fills in information gaps on NOAC use in patients age 80 and over.

ISMP reports that some patients have inadvertently taken double doses of rivaroxaban in dosing mixups.

A large observational study Sweden found that use of anticoagulants by patients with atrial fibrillation reduced the risk of dementia. 

A study found that treating patients with rivaroxaban for 45 days after hospital discharge reducedthe rate of nonfatal blood clots, but had no effect on fatal blood clots. 

A massive retrospective study compared several non-vitamin K antagonist oral anticoagulants (NOACs) to warfarin.

A reversal agent to stop serious bleeding in patients treated with apixaban and rivaroxaban has been approved.

Oral rivaroxaban may be preferable to injections of low-molecular-weight heparins for patients being treated for cancer.

A study found that apixaban is a safe alternative to VKAs for ablation of atrial fibrillation.

Andaxanet alfa has shown effectiveness for patients needing hemostasis.

Three medical groups have issued guidelines for the use of anticoagulants during cardiac surgery.